Beyond Access vs. Protection in Trials of Innovative Therapies-Reference-Cited by-同舟云学术

Beyond Access vs. Protection in Trials of Innovative Therapies

Published:2010-05-14 Issue:5980 Volume:328 Page:829-830
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

London Alex John¹,Kimmelman Jonathan²,Emborg Marina Elena³

Affiliation:

1. Department of Philosophy, Carnegie Mellon University, Pittsburgh, PA 15213, USA.

2. Biomedical Ethics Unit, Social Studies of Medicine, McGill University, Montreal, Quebec H3A 1X1, Canada.

3. Wisconsin National Primate Research Center and Department of Medical Physics, University of Wisconsin, Madison, WI 53705, USA.

Abstract

Review of first-in-human trials should safeguard the integrity of the scientific enterprise through a focus on preclinical and clinical study quality.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference20 articles.

1. Renovating the Heart

2. Alper J., Nat. Biotechnol. 27, 213 (2009).

3. California Institute for Regenerative Medicine press release; www.cirm.ca.gov/PressRelease_102809.

4. Lo B., et al.., Stem Cells 23, 1454 (2005).

5. Lancet 365, 1984 (2005).

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Benefits and Risks of Receiving Investigational Solid Tumor Drugs in Randomized Trials;Annals of Internal Medicine;2024-06

2. Constructing appropriate bioprinting regulations: the ethical importance of recognising a liminal technology;Journal of Medical Ethics;2023-07-14

3. How Risky Can Biomedical Research Be?;Philosophy and Medicine;2023

4. Empowering local research ethics review of antibacterial mass administration research;Infectious Diseases of Poverty;2022-09-28

5. The ethical anatomy of payment for research participants;Medicine, Health Care and Philosophy;2022-05-24